Literature DB >> 18378635

A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits.

Edmond J Remarque1, Bart W Faber, Clemens H M Kocken, Alan W Thomas.   

Abstract

Plasmodium falciparum apical membrane antigen 1 (PfAMA1), a candidate malaria vaccine, is polymorphic. This polymorphism is believed to be generated predominantly under immune selection pressure and, as a result, may compromise attempts at vaccination. Alignment of 355 PfAMA1 sequences shows that around 10% of the 622 amino acid residues can vary between alleles and that linkages between polymorphic residues occur. Using this analysis, we have designed three diversity-covering (DiCo) PfAMA1 sequences that take account of these linkages and, when taken together, on average incorporate 97% of amino acid variability observed. For each of the three DiCo sequences, a synthetic gene was constructed and used to transform the methylotrophic yeast Pichia pastoris, allowing recombinant expression. All three DiCo proteins were reactive with the reduction-sensitive monoclonal antibody 4G2, suggesting the DiCo sequences had conformations similar to those of naturally occurring PfAMA1. Rabbits were immunized with FVO strain PfAMA1 or with the DiCo proteins either individually or as a mixture. Antibody titers and the ability to inhibit parasite growth in vitro were determined. Animals immunized with the DiCo mix performed similarly to animals immunized with FVO AMA1 when measured against FCR3 strain parasites but outperformed animals immunized with FVO AMA1 when assessed against other strains. The levels of growth inhibition (approximately 70%) induced by the mix of three DiCo proteins were comparable for FVO, 3D7, and HB3, suggesting that a considerable degree of diversity in AMA1 is adequately covered. This suggests that vaccines based upon the DiCo mix approach provide a broader functional immunity than immunization with a single allele.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18378635      PMCID: PMC2423090          DOI: 10.1128/IAI.00170-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.

Authors:  Jerome Aucouturier; L Dupuis; S Deville; S Ascarateil; V Ganne
Journal:  Expert Rev Vaccines       Date:  2002-06       Impact factor: 5.217

2.  In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.

Authors:  Michael C Kennedy; Jin Wang; Yanling Zhang; Aaron P Miles; Farideh Chitsaz; Allan Saul; Carole A Long; Louis H Miller; Anthony W Stowers
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

3.  Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells.

Authors:  G H Mitchell; A W Thomas; G Margos; A R Dluzewski; L H Bannister
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

4.  Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.

Authors:  James M Burns; Patrick R Flaherty; Payal Nanavati; William P Weidanz
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

5.  Human leukocyte antigen class II alleles influence levels of antibodies to the Plasmodium falciparum asexual-stage apical membrane antigen 1 but not to merozoite surface antigen 2 and merozoite surface protein 1.

Authors:  Armead H Johnson; Rose G F Leke; Nancy R Mendell; Dewon Shon; Young Ju Suh; Dennis Bomba-Nkolo; Viviane Tchinda; Samuel Kouontchou; Lucy W Thuita; Anne Marie van der Wel; Alan Thomas; Anthony Stowers; Allan Saul; Ainong Zhou; Diane W Taylor; Isabella A Quakyi
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

6.  A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites.

Authors:  Olivier Silvie; Jean-François Franetich; Stéphanie Charrin; Markus S Mueller; Anthony Siau; Myriam Bodescot; Eric Rubinstein; Laurent Hannoun; Yupin Charoenvit; Clemens H Kocken; Alan W Thomas; Geert-Jan Van Gemert; Robert W Sauerwein; Michael J Blackman; Robin F Anders; Gerd Pluschke; Dominique Mazier
Journal:  J Biol Chem       Date:  2003-12-15       Impact factor: 5.157

Review 7.  Avoiding deceptive imprinting of the immune response to HIV-1 infection in vaccine development.

Authors:  Sybille Muller
Journal:  Int Rev Immunol       Date:  2004 Sep-Dec       Impact factor: 5.311

8.  High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion.

Authors:  Clemens H M Kocken; Chrislaine Withers-Martinez; Martin A Dubbeld; Annemarie van der Wel; Fiona Hackett; Augusto Valderrama; Michael J Blackman; Alan W Thomas
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

9.  Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro.

Authors:  Weiqing Pan; Daqing Huang; Qingfeng Zhang; Li Qu; Dongmei Zhang; Xiaoli Zhang; Xiangyang Xue; Feng Qian
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

10.  Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum.

Authors:  Julie Healer; Vince Murphy; Anthony N Hodder; Rosella Masciantonio; Alan W Gemmill; Robin F Anders; Alan F Cowman; Adrian Batchelor
Journal:  Mol Microbiol       Date:  2004-04       Impact factor: 3.501

View more
  65 in total

Review 1.  Vaccines for malaria: how close are we?

Authors:  Mahamadou A Thera; Christopher V Plowe
Journal:  Annu Rev Med       Date:  2011-11-10       Impact factor: 13.739

Review 2.  Blood stage vaccines for Plasmodium falciparum: current status and the way forward.

Authors:  Ruth D Ellis; Issaka Sagara; Ogobara Doumbo; Yimin Wu
Journal:  Hum Vaccin       Date:  2010-08

3.  Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1.

Authors:  Karen S Harris; Christopher G Adda; Madhavi Khore; Damien R Drew; Antonina Valentini-Gatt; Freya J I Fowkes; James G Beeson; Sheetij Dutta; Robin F Anders; Michael Foley
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

4.  Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria.

Authors:  Prakash Srinivasan; Emmanuel Ekanem; Ababacar Diouf; Michelle L Tonkin; Kazutoyo Miura; Martin J Boulanger; Carole A Long; David L Narum; Louis H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-23       Impact factor: 11.205

Review 5.  Malaria vaccine clinical trials: what's on the horizon.

Authors:  Alberto Moreno; Chester Joyner
Journal:  Curr Opin Immunol       Date:  2015-07-13       Impact factor: 7.486

6.  Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.

Authors:  Kazutoyo Miura; Raul Herrera; Ababacar Diouf; Hong Zhou; Jianbing Mu; Zonghui Hu; Nicholas J MacDonald; Karine Reiter; Vu Nguyen; Richard L Shimp; Kavita Singh; David L Narum; Carole A Long; Louis H Miller
Journal:  Infect Immun       Date:  2013-02-19       Impact factor: 3.441

7.  VAR2CSA Domain-Specific Analysis of Naturally Acquired Functional Antibodies to Plasmodium falciparum Placental Malaria.

Authors:  Justin Yai Alamou Doritchamou; Raul Herrera; Joan A Aebig; Robert Morrison; Vu Nguyen; Karine Reiter; Richard L Shimp; Nicholas J MacDonald; David L Narum; Michal Fried; Patrick E Duffy
Journal:  J Infect Dis       Date:  2016-05-18       Impact factor: 5.226

Review 8.  Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein.

Authors:  Francis B Ntumngia; Christopher L King; John H Adams
Journal:  Int J Parasitol       Date:  2012-10-12       Impact factor: 3.981

9.  Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity.

Authors:  Kwadwo A Kusi; Bart W Faber; Alan W Thomas; Edmond J Remarque
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

10.  Malaria vaccines: where next?

Authors:  Anthony A Holder
Journal:  PLoS Pathog       Date:  2009-10-30       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.